Celldex Therapeutics Inc
Closed
SectorHealthcare
32.82 1.77
Overview
Share price change
24h
Min
32.05
Max
33.51
Income | 2.6M -79M |
|---|---|
Sales | -60K 15K |
EPS | -1.18 |
Profit margin | -524,566.667 |
Employees | 198 |
EBITDA | 2.7M -78M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +58.11% upside |
Next Earnings | 5 Aug 2026 |
|---|
Market Cap | -51M 2.5B |
|---|---|
Previous open | 31.05 |
Previous close | 32.82 |
News Sentiment
By Acuity
50%
50%
155 / 342 Healthcare
Celldex Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
